Isolation of Mycoplasma hominis in critically ill patients with pulmonary infections: clinical and microbiological analysis in an intensive care unit

Intensive Care Medicine - Tập 33 - Trang 143-147 - 2006
Celia García1, Estibaliz Ugalde1, Idoia Monteagudo1, Ana Saez1, Jesús Agüero1,2, Luis Martinez-Martinez1,2, Eduardo Miñambres3
1Microbiology Service, University Hospital Marqués de Valdecilla, Santander, Spain
2Department of Molecular Biology, University of Cantabria, Santander, Spain
3Intensive Care Service, Hospital Universitario Marqués de Valdecilla, Santander, Spain

Tóm tắt

Mycoplasma hominis is a well recognized extragenital pathogen. However, it is an uncommon cause of respiratory infections in critically ill patients admitted to the intensive care unit (ICU). Prospective clinical investigation in a 21-bed ICU in a university hospital. Seven patients requiring intensive care who developed a ICU-acquired pneumonia in which M. hominis was recovered from bronchoalveolar lavage and pleural fluid cultures. M. hominis was isolated in all patients by use of conventional bacteriological cultures. All strains were identified by 16S rRNA gene sequencing analysis. Patients' charts were reviewed for each case of infection. Seven strains of M. hominis were isolated during a 4-year period. All of these isolates were recovered from adult men admitted to the ICU and all had clinical signs of pneumonia. In three patients treatment for M. hominis with quinolones was associated with a good clinical response. Suspicion of M. hominis pneumonia must be heightened particularly in critically ill patients. Therefore an understanding of the microbiology of this organism is essential to successfully treat patients with these infections that are not ordinarily covered with standard antibiotic therapy.

Tài liệu tham khảo

Azoulay E, Alberti C, Legendre I, Buisson CB, Le Gall JR; European Sepsis Group (2005) Post-ICU mortality in critically ill infected patients: an international study. Intensive Care Med 31:56–63 Acquarolo A, Urli T, Perone G, Giannotti C, Candiani A, Latronico N (2005) Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study. Intensive Care Med 31:510–516 Clec'h C, Timsit JF, De Lassence A, Azoulay E, Alberti C, Garrouste-Orgeas M, Mourvilier B, Troche G, Tafflet M, Tuil O, Cohen Y (2004) Efficacy of adequate early antibiotic therapy in ventilator-associated pneumonia: influence of disease severity. Intensive Care Med 30:1327–1333 Waites KB, Rikihisa Y, Taylor-Robinson D (2003) Mycoplasma and ureaplasma. In: Murray PR, Baron EJ, Jorgensen JM, Pfaller MA, Yolken RH (eds) Manual of clinical microbiology. American Society for Microbiology, Washington, pp 972–990 Meyer RD, Clough W (1993) Extragenital Mycoplasma hominis infections in adults: emphasis on immunosuppression. Clin Infect Dis 17(Suppl 1):243–249 Waites KB, Bébéar CM, Robertson JA, Talkington DF, Kenny GE (2001) Cumitech 34. Nolte FS (ed) Laboratory diagnosis of mycoplasmal infections. American Society for Microbiology, Washington Saez A, Monteagudo I, Miñambres E, Ots E, Rodriguez-Borregan JC, García C (2003) Pneumonia due to Mycoplasma hominis in a healthy adult. Scand J Infect Dis 35:282–284 Izenberg HD (2003) Respiratory tract cultures.– In: Clinical microbiology. Procedures handbook, 2nd edn, vol 1. ASM, Washington Kuppeveld FJ van, van der Logt JT, Angulo AF, van Zoest MJ, Quint WG, Niesters HG, Galama JM, Melchers WJ (1992) Genus- and species-specific identification of mycoplasmas by16S rRNA amplification. Appl Environ Microbiol 58:2606–2615 Roberts MC (1992) Antibiotic resistance. In: Maniloff J (ed) Mycoplasmas: molecular biology and pathogenesis. American Society for Microbiology, Washington, pp 513–523 Dosa E, Nagy E, Falk W, Szoke I, Ballies U (1999) Evaluation of the Etest for susceptibility testing of Mycoplasma hominis and Ureaplasma urealyticum. J Antimicrob Chemother 43:575–578 Mufson MA (1983) Mycoplasma hominis: a review of its role as a respiratory tract pathogen of humans. Sex Transm Dis 10(Suppl 4):226–229 Lyon GM, Alspaugh JA, Meredith FT, Harrell LJ, Tapson V, Davis RD, Kanj SS (1997) Mycoplasma hominis pneumonia complicating bilateral lung transplantation: case report and review of the literature. Chest 112:1428–1432 Giantsou E, Liratzopoulos N, Efraimidou E, Panopoulou M, Alepopoulou E Kartali-Ktenidou S, Minopoulos GI, Zakynthinos S, Manolas KI (2005) Both early-onset and late-onset ventilator-associated pneumonia are caused mainly by potentially multiresistant bacteria. Intensive Care Med 31:1488–1494 Hubmayr RD, Burchardi H, Elliot M, Fessler H, Georgopoulos D, Jubran A, Limper A, Pesenti A, Rubenfeld G, Stewart T, Villar J (2002) Statement of the 4th International Consensus Conference in Critical Care on ICU-Acquired Pneumonia-Chicago, Illinois, May 2002. Intensive Care Med 28:1521–1536 Waites KB, Canupp KC (2001) Evaluation of BacT/ALERT system for detection of Mycoplasma hominis in simulated blood cultures. J Clin Microbiol 39:4328–4331 Davies S, Spencer RC (1998) Effect of blood culture media on the in vitro recovery of Mycoplasma hominis. J Infect 17:215–220 Combes A, Figliolini C, Trouillet JL, Kassis N, Wolff M, Gibert C, Chastre J (2002) Incidence and outcome of polymicrobial ventilator-associated Pneumonia. Chest 121:1618–1623 Kenny G, Cartwright F (2001) Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 45:2604–2608 Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474